Companies researching Vaxzevria

Vaxzevria, previously known as the AstraZeneca COVID‑19 vaccine, is a pharmaceutical vaccine that reduces the risk of COVID‑19 infection in adults by using a modified adenovirus vector that carries the SARS‑CoV‑2 spike‑protein gene.

Frequently asked questions